ANNEX 4
RECOMMENDATIONS ON COMPOUNDS ON THE AGENDA
Acceptable Daily Recommended
Intake (ADI) Maximum Residue
Substance for human beings Level (MRL)
Anthelmintic drug
Albendazole 0.0.05 mg per kg Muscle, fat, and milk;
of body weight 0.1 mg/kg
Liver and kidney:
5 mg/kg
Anti-protozoal agents (5-Nitroimidazoles)
Dimetridazole Not allocated1 No MRLs allocated1
Ipronidazole Not allocated1 No MRLs allocated1
Metronidazole Not evaluated2 No MRLs allocated2
Ronidazole 0-0.025 mg per kg No MRLs allocated4
of body weight3
Antimicrobial sulfonamides
Sulfadimidine5 0-0.004 mg per kg Meat, liver, kidney,
of body weight3 and fat: 0.3 mg/kg as
total residue; 0.1 mg/kg
as sulfadimidine
Milk: 0.05 mg/kg as total
residue; 0.025 mg/kg
as sulfadimidine
Sulfathiazole Not allocated1 No MRLs allocated1
Growth promoter
Trenbolone acetate 0-0.02 µg per kg Muscle: 2 µg per kg
body weight as ß-trenbolone
Liver: 10 µg per kg
as alpha-trenbolone
Trypanosides
Diminazene Not allocated1 No MRLs allocated1
Isometadmidum Not allocated1 No MRLs allocated1
1. Insufficient toxicological information was available to establish
either an ADI or MRL (see Annex 5).
2 This substance was not evaluated because toxicological data were
not made available to the Committee.
3. Temporary acceptance (see Annex 5).
4. Insufficient information was available to establish MRLs
(See Annex 5).
5. This substance was on the agenda under the name "sulfamethazine".
It was evaluated under the name "sulfadimidine", which is the INN
(International Non-proprietary Names) designation for this
compound.